New hope for rare cancers: daratumumab trial targets Hard-to-Treat lymphomas
NCT ID NCT05907759
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab is given as a shot under the skin weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks for up to 2 years. The main goal is to see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab (a drug that targets a protein on cancer cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with these rare, hard-to-treat blood cancers.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects like infusion reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KSHV ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to lock in remission for rare lymphoma
- New hope for HIV patients with aggressive lymphoma: early trial launches
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- Gene therapy takes on HIV and cancer in one shot
- New combo tackles rare, aggressive lymphoma
- Experimental drug shows promise for Tough-to-Treat lymphoma